Steve Empoliti Joins Precision for Medicine as Chief Commercial Officer
Steve Empoliti Joins Precision for Medicine as Chief Commercial Officer
PR Newswire
BETHESDA, Md., May 30, 2024
Empoliti to lead Precision for Medicine commercial strategy, accelerate growth and leadership in next generation drug development
BETHESDA, Md., May 30, 2024 /PRNewswire/ -- Precision for Medicine, a global leader in biomarker-driven clinical research and development, today announced that Steve Empoliti has joined the organization as Chief Commercial Officer. In this newly created role, Mr. Empoliti will lead Precision for Medicine's commercial functions, with a singular focus on positioning Precision as the premier partner to help innovators accelerate the availability of life-changing medicines to patients.
Mr. Empoliti comes to Precision with a high-performance track record generated over three decades and across diverse industry experiences, including strategic consulting with Accenture and McKinsey & Company, operations and product management at Merck and Shire, and executive sales and marketing leadership at both PPD and Thermo Fisher Scientific. Most recently, Mr. Empoliti was the Global Head of Commercial at PPD, where he helped lead its successful integration with Thermo Fisher Scientific.
Chad Clark, President of Precision for Medicine, says, "I am delighted to add a talented and proven leader like Steve to our team. We have a unique breadth of expertise and capabilities that support life sciences innovators. Steve has the industry acumen to understand what clients truly need to advance their discoveries and demonstrate how Precision can help them achieve success."
Mr. Empoliti is enthusiastic about joining the Precision for Medicine team and contributing to the goal of accelerating the delivery of innovative therapies to patients. "It is a rare privilege to join a group of such highly experienced professionals, all focused on delivering truly innovative therapies to patients in need. I look forward to being part of this team, and to contributing to the important work ahead."
About Precision for Medicine
Precision for Medicine is the first biomarker-driven clinical research and development services organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies a transformational approach to clinical research that integrates clinical trial design and execution with deep scientific knowledge, laboratory expertise, data intelligence and advanced manufacturing solutions. This convergence is driving faster clinical development and approval. Precision for Medicine is part of Precision Medicine Group, with 3,500 people in 40 locations globally across North America, Europe and Asia-Pacific. For more information, visit PrecisionForMedicine.com
For more information contact:
GCI Health
PrecisionGCIHealth@gcihealth.com
SOURCE PRECISION FOR MEDICINE
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
13 Charts On the Market’s Q2 Turnaround
-
10 Top-Performing Dividend Stocks of Q2 2024
-
Markets Brief: US Jobs Report In View as Q3 Begins
-
Q3 2024 Stock Market Outlook: Is the AI Stock Trade Over?
-
Ian Bremmer: 4 Big Geopolitical Risks to Watch
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Energy: OPEC Continues to Operate From a Position of Weakness With Production Cuts Extension
-
Communication Services: Online Advertising Remains Strong, but Growth Will Likely Decelerate
-
3 Stocks to Buy This Summer While They’re Seriously Undervalued
-
10 Top Dividend Stocks for 2024
-
Finding Small-Cap Stock Opportunities In a Big-Cap World
-
The 10 Best Companies to Invest in Now
-
Nike Earnings: Dim Sales Outlook Slams Shares, but Patient Investors Could Be Rewarded